Cite
HARVARD Citation
Weber, J. et al. (2023). Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of clinical oncology. 41 (3), pp. 517-527. [Online].